Taiwan-based clinical-stage biopharmaceutical company Senhwa Biosciences Inc (TPEx:6492) announced on Tuesday the signing of a Memorandum of Understanding (MOU) with GEM YIELD BAHAMAS LIMITED, an affiliate of global investment firm Global Emerging Markets (GEM).

Under the agreement, GEM intends to provide up to TWD500m in strategic funding to support Senhwa's advancing pipeline, AI-enabled drug discovery initiatives, and global expansion strategy.

In addition to its ongoing focus on cancer immunotherapy, Senhwa has been actively building an AI-driven discovery platform. Through strategic collaboration with Y combinator backed AI Native companies such as CellType, the company is leveraging next-generation C2S (cell-to-sentence) technology to deepen mechanistic insights and systematically identify potential combination therapy in treating different types of cancers.

Senhwa says that AI-enabled validation has demonstrated that its lead candidates possess promising immunomodulatory potential under specific tumour microenvironment conditions.

GEM, headquartered in Luxembourg with offices in Paris, New York and Nassau (Bahamas), is an alternative investment group focused on emerging markets.

Senhwa believes that this strategic capital commitment will enable it to advance its clinical programmes in parallel with its AI-driven discovery platform, further strengthening its competitive position within the global biopharmaceutical ecosystem.